Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients with Advanced Solid Tumours

Trial Identifier: D6015C00001
Sponsor: AstraZeneca
NCTID:: NCT02482311
Start Date: July 2015
Primary Completion Date: January 2018
Study Completion Date: August 2019
Condition: Ovarian Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation
French Translation

Trial Locations

Country Location
CA, AB Edmonton, AB, CA, T6G 1Z2
CA, BC Vancouver, BC, CA, V5Z 4E6
CA, ON Toronto, ON, CA, M5G 2M9
US, AR Fayetteville, AR, US, 72703
US, CA San Francisco, CA, US, 94143
US, CA West Hollywood, CA, US, 90048
US, FL Ft Myers, FL, US, 33905
US, IN Indianapolis, IN, US, 46202
US, MI Detroit, MI, US, 48201
US, NC Charlotte, NC, US, 28204
US, OK Oklahoma City, OK, US, 73104
US, PA Philadelphia, PA, US, 19104
US, SC Greenville, SC, US, 29605
US, TN Nashville, TN, US, 37203
US, TX Houston, TX, US, 77030
US, WI Milwaukee, WI, US, 53226